Elanco Animal Health (ELAN) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
15 Sep, 2026Market trends and industry outlook
Pet health market is projected to grow from $40B to $60B over the next decade, driven by durable demand and innovation.
Pet spending remains resilient, with 80% of companies in the sector growing in the first half of the year.
The farm animal segment is benefiting from global protein demand, with dairy and poultry as key growth drivers and a five-year beef shortage impacting the market.
Omni-channel and online purchasing are increasing, with 40% of pet care now subscription-based, boosting compliance and sales.
The company is well-positioned for continued growth, with innovation and commercial execution as core strategies.
Product innovation and portfolio performance
Innovation is the main growth driver, especially for products like Zenrelia, Quattro, and Befrena, which are gaining share and expanding clinic penetration.
The derm and parasiticide markets are growing, with differentiated products enabling price increases and new clinic additions.
Vaccine and therapeutic portfolios are seeing a halo effect from innovation, leading to increased market share and stability.
Credelio Quattro is expected to become the largest brand family, with international launches planned for next year.
Zenrelia and Befrena are driving growth in the derm market, with strong adoption and plans for further label improvements.
Financial performance and guidance
Pricing accelerated in July and August, with broad-based increases across pharma and pet segments.
Organic growth targets have been raised, with innovation-led growth expected to continue through 2027 and beyond.
Margin improvements are anticipated through fixed cost leverage and the Ascend program, targeting 60% gross margins.
Investments in manufacturing and R&D are expected to normalize after 2026, with no anticipated capacity gaps.
The company remains opportunistic in talent acquisition, leveraging market disruptions to strengthen its team.
Latest events from Elanco Animal Health
- Q2 2026 saw double-digit revenue growth, margin expansion, and raised full-year guidance.ELAN
Q2 2026 - Innovation and operational efficiency drive growth and margin expansion across pet and farm segments.ELAN
Piper Sandler 37th Annual Healthcare Conference - Innovation pipeline and global reach drive strong growth and raised financial targets.ELAN
46th Annual William Blair Growth Stock Conference - Innovation and resilient pricing drive strong growth in animal health and farm segments.ELAN
Stifel Jaws & Paws Conference 2026 - Strong growth, innovation, and all proposals approved, with new blockbusters targeted by 2031.ELAN
AGM 2026 - Q1 2026 revenue up 15% to $1.371B, with raised guidance and strong innovation momentum.ELAN
Q1 2026 - Q1 2025 saw 4% organic growth, raised guidance, and accelerated debt paydown on strong innovation.ELAN
Q1 2025 - Blockbuster launches and innovation pipeline drive strong growth and sustainability in 2025.ELAN
43rd Annual J.P. Morgan Healthcare Conference 2025 - 2024 saw organic growth, margin gains, and debt reduction; 2025 targets innovation-led expansion.ELAN
Q4 2024